...
首页> 外文期刊>Clinical Biochemistry >Evaluation of cytokeratin-19 & cytokeratin-20 and interleukin-6 in Egyptian bladder cancer patients.
【24h】

Evaluation of cytokeratin-19 & cytokeratin-20 and interleukin-6 in Egyptian bladder cancer patients.

机译:埃及膀胱癌患者中细胞角蛋白19,细胞角蛋白20和白细胞介素6的评估。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: This study was designed to detect the expression of CK-19 and CK-20 in tissue specimens and IL-6 in the sera (as a noninvasive maneuver) of bladder cancer patients. Results were correlated with the clinico-pathologic parameters, Bilharziasis and the occurrence of relapse of the carcinoma among Egyptian bladder cancer patients. METHODS: Subjects of this study were 50 cases of bladder carcinoma (19 cases were positive for Bilharziasis) as well as 20 cystitis cases as control (7 cases were positive for Bilharziasis). Messenger ribonucleic acid extracted from fresh frozen tissue specimens with bladder tumor and the control group were collected and subjected to RT-PCR to detect expression of the amplification bands of CK-19 and CK-20 (214 and 370 base pairs). In the mean time, Interleukin-6 was quantified in the sera of the patients using ELISA kit. RESULTS: CK-19 and CK-20 RNAs were expressed in bladder cancer cases, but not expressed in the control group. They were significantly correlated to advanced tumor stage and grade, while CK-19 positivity, was also, correlated to tumor recurrence and tumor pathology being more in SCC than TCC. Moreover, IL-6 positivity was correlated to the occurrence of malignancy, advanced grade and pathology being more in SCC than TCC. ROC curve was utilized to choose the best cut-off for serum IL-6 (49.2 pg/mL). At the determined cut-off, the sensitivity was 66% and the specificity was 95%. Bilharziasis was found to be related to advanced stages and grades of bladder cancer. CONCLUSION: CK-19, CK-20 and IL-6 were strongly associated with malignant phenotype of Egyptian bladder tissues, so they may be used as additional markers for assessment of bladder cancer patients.
机译:目的:本研究旨在检测膀胱癌患者组织样本中CK-19和CK-20的表达以及血清IL-6(作为非侵入性操作)的表达。结果与埃及膀胱癌患者的临床病理参数,比拉菌病和癌症复发的发生有关。方法:本研究的受试者为50例膀胱癌(19例Bilharziasis阳性)和20例膀胱炎病例为对照(7例Bilharziasis阳性)。收集从新鲜的具有膀胱肿瘤的冷冻组织标本和对照组中提取的信使核糖核酸,并进行RT-PCR以检测CK-19和CK-20的扩增条带(214和370个碱基对)的表达。同时,使用ELISA试剂盒对患者血清中的白介素-6进行定量。结果:CK-19 RNAs在膀胱癌中表达,而在对照组中则不表达。它们与晚期肿瘤分期和分级显着相关,而CK-19阳性也与SCC中的肿瘤复发和肿瘤病理学相关性高于TCC。而且,IL-6阳性与SCC中恶性肿瘤的发生,晚期分级和病理学相关性高于TCC。利用ROC曲线为血清IL-6(49.2 pg / mL)选择最佳临界值。在确定的临界值时,灵敏度为66%,特异性为95%。发现比尔哈齐斯病与膀胱癌的晚期和等级有关。结论:CK-19,CK-20和IL-6与埃及膀胱组织的恶性表型密切相关,因此它们可作为评估膀胱癌患者的其他标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号